JP Morgan Chase
EGRX

JP Morgan Chase’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

JP Morgan Chase’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,300
Closed -$244K – 5771
2020
Q1 		$244K Buy
+5,300
New +$266K ﹤0.01% 4185

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase's EGRX Position: Q3 2024 in Review

JP Morgan Chase sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 2,317 shares — an estimated $13K sold.

JP Morgan Chase first reported a position in EGRX in Q1 2014 and held it in 33 quarters. The position peaked at $18.5M in Q3 2021. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • JP Morgan Chase reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • JP Morgan Chase sold 2,317 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $13K.
  • JP Morgan Chase first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 33 quarters.
  • JP Morgan Chase's Eagle Pharmaceuticals, Inc. position peaked at $18.5M in Q3 2021.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.